IDH1 and central nervous system cancer: The phase III INDIGO trial has demonstrated the efficacy of the dual IDH1/2 inhibitor vorasidenib in IDH-mutant gliomas, which led to a priority review by the FDA and highlights the need for molecular profiling and precision medicine in this field12.